A preclinical randomized controlled multi-centre trial of anti-interleukin-17A treatment for acute ischaemic stroke
Open Access
- 2 March 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 5 (2) , fcad090
Abstract
Multiple consensus statements have called for preclinical randomized controlled trials to improve translation in stroke research. We investigated the efficacy of an interleukin-17A neutralizing antibody in a multi-centre preclinical randomized controlled trial using a murine ischaemia reperfusion stroke model. Twelve-week-old male C57BL/6 mice were subjected to 45 min of transient middle cerebral artery occlusion in four centres. Mice were randomly assigned (1:1) to receive either an anti-interleukin-17A (500 µg) or isotype antibody (500 µg) intravenously 1 h after reperfusion. The primary endpoint was infarct volume measured by magnetic resonance imaging three days after transient middle cerebral artery occlusion. Secondary analysis included mortality, neurological score, neutrophil infiltration and the impact of the gut microbiome on treatment effects. Out of 136 mice, 109 mice were included in the analysis of the primary endpoint. Mixed model analysis revealed that interleukin-17A neutralization significantly reduced infarct sizes (anti-interleukin-17A: 61.77 ± 31.04 mm3; IgG control: 75.66 ± 34.79 mm3; P = 0.01). Secondary outcome measures showed a decrease in mortality (hazard ratio = 3.43, 95% confidence interval = 1.157–10.18; P = 0.04) and neutrophil invasion into ischaemic cortices (anti-interleukin-17A: 7222 ± 6108 cells; IgG control: 28 153 ± 23 206 cells; P < 0.01). There was no difference in Bederson score. The analysis of the gut microbiome showed significant heterogeneity between centres (R = 0.78, P < 0.001, n = 40). Taken together, neutralization of interleukin-17A in a therapeutic time window resulted in a significant reduction of infarct sizes and mortality compared with isotype control. It suggests interleukin-17A neutralization as a potential therapeutic target in stroke.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (T.M. 4248778651, 428778375)
- Schilling Foundation
This publication has 57 references indexed in Scilit:
- Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic strokeBlood, 2012
- A call for transparent reporting to optimize the predictive value of preclinical researchNature, 2012
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- International, Multicenter Randomized Preclinical Trials in Translational Stroke Research: It's Time to ActJournal of Cerebral Blood Flow & Metabolism, 2012
- Emulating Multicentre Clinical Stroke Trials: A New Paradigm for Studying Novel Interventions in Experimental Models of StrokeInternational Journal of Stroke, 2009
- Induction of Intestinal Th17 Cells by Segmented Filamentous BacteriaCell, 2009
- Pivotal role of cerebral interleukin-17–producing γδT cells in the delayed phase of ischemic brain injuryNature Medicine, 2009
- 1,026 Experimental treatments in acute strokeAnnals of Neurology, 2006
- Noninvasive Quantification of Brain Edema and the Space-Occupying Effect in Rat Stroke Models Using Magnetic Resonance ImagingStroke, 2004
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995